Alan S Wayne

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
    A S Wayne
    Department of Pediatrics, Division of Pediatric Hematology Oncology, Sickle Cell Center, and Pediatric Pharmacy Department, University of Miami School of Medicine, Jackson Memorial Medical Center, Miami, FL, USA
    Blood 96:2369-72. 2000
  2. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 13N240, 10 Center Drive, MSC 1928, Bethesda, MD 20892 1928, USA
    Hematol Oncol Clin North Am 17:1243-60. 2003
  3. pmc Immunotherapy of childhood cancer: from biologic understanding to clinical application
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1 3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892 1104, USA
    Curr Opin Pediatr 22:2-11. 2010
  4. pmc Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1104, USA
    Clin Cancer Res 16:1894-903. 2010
  5. pmc Hematopoietic stem cell transplantation for leukemia
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1 3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892 1104, USA
    Pediatr Clin North Am 57:1-25. 2010
  6. doi request reprint Application of immunotherapy in pediatric leukemia
    Alan S Wayne
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W 3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 4:159-66. 2009
  7. pmc Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8
    Xiaobo Hu
    Laboratory of Molecular Biology, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD, USA
    Leuk Res 37:1551-6. 2013
  8. pmc Immune-based therapeutics for pediatric cancer
    Christian M Capitini
    National Cancer Institute, National Institutes of Health, Center for Cancer Research, Pediatric Oncology Branch, 10 Center Drive, MSC 1104, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 10:163-78. 2010
  9. pmc Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States
    Jeffrey I Cohen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20892, USA
    Blood 117:5835-49. 2011
  10. ncbi request reprint Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland Electronic address
    Biol Blood Marrow Transplant 20:1033-9. 2014

Detail Information

Publications43

  1. ncbi request reprint Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
    A S Wayne
    Department of Pediatrics, Division of Pediatric Hematology Oncology, Sickle Cell Center, and Pediatric Pharmacy Department, University of Miami School of Medicine, Jackson Memorial Medical Center, Miami, FL, USA
    Blood 96:2369-72. 2000
    ..These data should be considered in reference to cost and efficacy analyses of alternative therapies for sickle cell disease, such as allogeneic bone marrow transplantation...
  2. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 13N240, 10 Center Drive, MSC 1928, Bethesda, MD 20892 1928, USA
    Hematol Oncol Clin North Am 17:1243-60. 2003
    ..Efforts to improve outcome for older patients and for patients with alternative donors have led to decreased treatment-associated complications with associated better long-term DFS...
  3. pmc Immunotherapy of childhood cancer: from biologic understanding to clinical application
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1 3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892 1104, USA
    Curr Opin Pediatr 22:2-11. 2010
    ..This review summarizes the biologic basis of cancer immunotherapy and highlights recent examples of progress in the application of novel humoral and cellular immunotherapies to children and adolescents with malignancy...
  4. pmc Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1104, USA
    Clin Cancer Res 16:1894-903. 2010
    ..We conducted the first preclinical and phase I clinical studies of BL22 in that setting...
  5. pmc Hematopoietic stem cell transplantation for leukemia
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1 3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892 1104, USA
    Pediatr Clin North Am 57:1-25. 2010
    ..The characteristics of these high-risk subgroups and the role of HSCT in childhood leukemias are discussed...
  6. doi request reprint Application of immunotherapy in pediatric leukemia
    Alan S Wayne
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W 3750, 9000 Rockville Pike, MSC 1104, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 4:159-66. 2009
    ..Efforts to apply new immunotherapy approaches to the treatment of leukemia in pediatrics have recently begun. The optimal reagents, methods, and regimens have yet to be fully defined. Ongoing clinical trials offer promise in that regard...
  7. pmc Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8
    Xiaobo Hu
    Laboratory of Molecular Biology, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD, USA
    Leuk Res 37:1551-6. 2013
    ..Resistance was associated with methylation of the CpG island in the DPH1 promoter. 5-Azacytidine prevented resistance and methylation of the CpG residues and merits evaluation to determine if it can increase the efficacy of HA22 in ALL. ..
  8. pmc Immune-based therapeutics for pediatric cancer
    Christian M Capitini
    National Cancer Institute, National Institutes of Health, Center for Cancer Research, Pediatric Oncology Branch, 10 Center Drive, MSC 1104, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 10:163-78. 2010
    ..Elucidation of the principles of tumor biology and the development of novel laboratory technologies over the last decade have led to substantial progress in bringing immunotherapies to the bedside...
  9. pmc Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States
    Jeffrey I Cohen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20892, USA
    Blood 117:5835-49. 2011
    ..These studies are registered at http://www.clinicaltrials.gov as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific T-cell studies, and NCT00578539 for the hematopoietic stem cell transplantation protocol...
  10. ncbi request reprint Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland Electronic address
    Biol Blood Marrow Transplant 20:1033-9. 2014
    ..Validation in a larger independent homogenous cohort is needed to develop a prognostic tool for clinical use to predict post-transplantation relapse...
  11. pmc Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas
    Kristin Baird
    Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 18:698-707. 2012
    ..Enhanced chemo- and radiosensitivity of tumors and normal tissues was observed posttransplantation...
  12. pmc Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans
    Fabio Candotti
    Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health NIH, Bethesda, MD, USA
    Blood 120:3635-46. 2012
    ..These studies directly demonstrate the importance of providing nonmyeloablative pretransplantation conditioning to achieve therapeutic benefits with gene therapy for ADA-deficient severe combined immunodeficiency...
  13. pmc Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency
    Chimene Kesserwan
    Genetics and Molecular Biology Branch and the Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 4442, USA
    J Allergy Clin Immunol 129:762-769.e1. 2012
    ..This malignancy is rarely diagnosed in childhood...
  14. pmc Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates
    David J FitzGerald
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Cancer Res 71:6300-9. 2011
    ..Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens...
  15. pmc A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene
    Hui Wei
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 288:12305-12. 2013
    ..The abnormal methylation appeared to be catalyzed by DPH5. Inactivation of the WDR85 gene could be a mechanism of immunotoxin resistance in patients undergoing immunotoxin therapy...
  16. pmc Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation
    Ronald E Gress
    Experimental Transplantation Immunology Branch, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland
    Biol Blood Marrow Transplant 19:1537-45. 2013
    ....
  17. pmc Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain
    Andre Larochelle
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 119:1848-55. 2012
    ....
  18. pmc Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
    Hui Wei
    Laboratory of Molecular Biology and Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 109:6898-903. 2012
    ..Incubation of sensitive cells with the methylation inhibitor 5-azacytidine prevented the emergence of resistant cells, suggesting that this agent in combination with HA22 may be useful in the treatment of some cases of ALL...
  19. ncbi request reprint Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia
    Francis Mussai
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Br J Haematol 150:352-8. 2010
    ..These results provide a strong rationale for clinical testing of this agent in children with drug-resistant ALL and offers the potential to reduce morbidities of treatment while improving outcome...
  20. pmc Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
    Waleed Haso
    Pediatric Oncology Branch, Center for Cancer Research CCR, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 121:1165-74. 2013
    ..We conclude that second-generation m971 mAb-derived anti-CD22 CARs are promising novel therapeutics that should be tested in BCP-ALL...
  21. pmc Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications
    Armin G Jegalian
    Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Haematologica 95:1873-9. 2010
    ..Blastic plasmacytoid dendritic cell neoplasm is a rare malignancy that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited...
  22. doi request reprint Variables affecting the quantitation of CD22 in neoplastic B cells
    Gregory A Jasper
    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytometry B Clin Cytom 80:83-90. 2011
    ....
  23. pmc Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia
    Margarita Raygada
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Developmental Genetics, Bethesda, MD 20892 1831, USA
    Pediatr Blood Cancer 54:173-5. 2010
    ..The patient underwent bone marrow transplantation and is currently in remission. Children with concurrent cutaneous café-au-lait and JXG lesions should be evaluated and monitored closely for the possible development of JMML...
  24. ncbi request reprint Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease
    M R Robinson
    National Eye Institute NIH, 10 10S229, 110 Center Drive, MSC 1863, Bethesda, MD 20892 1863, USA
    Bone Marrow Transplant 33:1031-5. 2004
    ..Additional studies are required to determine the long-term safety and efficacy of topical corticosteroids for cicatricial conjunctivitis associated with ocular GVHD in the context of a randomized, prospective clinical trial...
  25. ncbi request reprint Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation
    Pamela Stratton
    Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland 20892 1109, USA
    Obstet Gynecol 110:1041-9. 2007
    ..To describe the diagnosis and management of female genital chronic graft-versus-host (GVH) disease, a complication of hematopoietic stem cell transplantation...
  26. pmc Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease
    Kristin Baird
    Pediatric Oncology Branch, Center for Cancer Research CCR, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD, USA
    Transfus Apher Sci 41:209-16. 2009
    ..Here we review the experience of extracorporeal photo-apheresis for the treatment of steroid refractory acute and chronic graft versus host disease based on the current literature...
  27. pmc National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Biol Blood Marrow Transplant 17:443-54. 2011
    ..These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT...
  28. ncbi request reprint Thromboembolic events in children and young adults with pediatric sarcoma
    Ido Paz-Priel
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
    J Clin Oncol 25:1519-24. 2007
    ..Adults with malignancy are at increased risk for venous thromboembolic events (TEs). However, data in children and young adults with cancer are limited...
  29. pmc The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 115:3017-24. 2010
    ..However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death. This trial was registered at www.clinicaltrials.gov as NCT000019253...
  30. pmc Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia
    Nirali N Shah
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland Pediatric Oncology, Johns Hopkins University, Baltimore, Maryland Electronic address
    Biol Blood Marrow Transplant 20:1000-7. 2014
    ..Our results suggest that early intervention strategies targeting post-transplantation MRD for relapse prevention in acute leukemia may not be feasible...
  31. pmc Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies
    Hema Dave
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    PLoS ONE 7:e52655. 2012
    ..The receptor tyrosine kinase ROR1 has emerged as a candidate for mAb targeting in select B-cell malignancies...
  32. pmc Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype
    Brad Moriyama
    Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
    Pharmacotherapy 33:e19-22. 2013
    ..If an obese patient dosed on total body weight is also a CYP2C19 poor metabolizer, serum voriconazole concentrations will be further elevated, potentially leading to drug-induced toxicity...
  33. doi request reprint Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and ther
    Rachel Rau
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1104, USA
    Pediatr Infect Dis J 27:265-8. 2008
    ..She was treated with acyclovir and subsequently developed VZV antigen-positive zoster. Detection of VZV DNA in blood may be useful for early diagnosis in immunocompromised hosts who present with zoster without skin lesions...
  34. pmc Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency
    Robert Sokolic
    Disorders of Immunity Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA
    Blood 118:2688-94. 2011
    ..These trials were registered at www.clinicaltrials.gov as #NCT00018018 and #NCT00006319...
  35. ncbi request reprint Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis
    Kouhei Yamashita
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 12:22-30. 2006
    ..The contrasting change in central memory cells (CD8(+) increased versus CD4(+) decreased) in cGVHD provide support for recent reports suggesting unique differences in the differentiation pathways for CD8(+) versus CD4(+) T cells...
  36. pmc Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells
    Hua Zhang
    Pediatric Oncology Branch, NCI, NIH Clinical Center, Bethesda, MD, USA
    J Immunother 34:187-95. 2011
    ..We conclude that KIR mismatch is not a prerequisite for tumor killing by CD137L/IL15 NK cells and that NCR expression provides a biomarker for predicting potency of CD137L/IL15 NK cells in studies of NK cell-based immunotherapy...
  37. pmc Hematopoietic stem cell donation in children: a review of the sibling donor experience
    Lori S Wiener
    Pediatric Psychosocial Support and Research Program, National Cancer Institute, 9000 Rockville Pike Bldg 10, Bethesda, MD 20892, USA
    J Psychosoc Oncol 25:45-66. 2007
    ....
  38. ncbi request reprint Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database
    John J Strouse
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 23:4735-41. 2005
    ..To evaluate risk factors for the development of and factors influencing survival in pediatric melanoma...
  39. ncbi request reprint Psychotropic medication use in pediatric patients with cancer
    Maryland Pao
    Office of the Clinical Director, National Institute of Mental Health, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Pediatr Adolesc Med 160:818-22. 2006
    ..While increased use of psychotropic medications in children and adolescents in the general population has been reported, little is known about the prescribing practices for these medications in medically ill children...
  40. ncbi request reprint Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  41. ncbi request reprint Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis
    Kamar Godder
    Autologous Blood and Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    J Clin Oncol 22:3798-804. 2004
    ..To determine prognostic factors correlated with outcomes after autologous hematopoietic stem-cell transplantation (HSCT) in children with acute myeloid leukemia (AML)...
  42. doi request reprint Progress in the curative treatment of childhood hematologic malignancies
    Alan S Wayne
    J Natl Cancer Inst 100:1271-3. 2008